2018 General Meeting

On the 7th of December 2017, Advanced Oncotherapy (the “Company) announced an exclusive distribution agreement for China and other geographies as well as new equity investments for a total consideration of £37 million (LINK 1: AVO ANNOUNCEMENT 7 dec 17) (altogether the Transactions). As per the notice dated 28th of December 2017 (LINK 2: NOTICE OF SHAREHOLDER MEETING 28 dec 17), the Board of the Company is seeking shareholder authority for the issue of equity securities in relation to the Transactions and additional authority for general use. The circular – which gives further background on the Transactions – and the Form of Proxy for use by Shareholders in connection with the General Meeting are available in the links below.

Online voting is available on the website of the Registrars at www.signalshares.com where instructions are provided. Alternatively, you can complete the Form of Proxy in accordance with the instructions printed on to the Company's Registrars and:

  • Scan and email them to AVO, or
  • Post them to: Link Asset Services (FAO: Aydin Djemal), PXS, 34 Beckenham Road, Beckenham, Kent, BR3 4TU, to be received by no later than 10.00 a.m. on Sunday, 21 January 2018

CREST members may appoint proxies by using the CREST electronic proxy appointment service and transmitting a CREST Proxy Instruction in accordance with the procedures set out in the CREST Manual so that it is received by Link Asset Services (under CREST ID: RA10) by no later than 10.00 a.m. on Sunday, 21 January 2018. The time of receipt will be taken to be the time from which Link Asset Services is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. Completion and return of a Form of Proxy or transmitting a CREST Proxy Instruction will not prevent a Shareholder from attending the General Meeting and voting in person should he or she wish to do so. This General Meeting – to be held at the Royal Institute of British Architects, 66 Portland Place, London W1B 1AD – is being convened on 23rd of January 2018 at 10.00am UK.

For further information contact:

Advanced Oncotherapy plc

Nicolas Serandour, Chief Executive Officer

Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Stockdale Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten

Stifel Nicolaus Europe (Joint Broker)

Tel: +44 20 7710 7600

Jonathan Senior / Ben Maddison

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780

Paul McManus / Anna Dunphy

avo@walbrookpr.com